文献速递心脑血管急症消化、代谢与肾脏急症

盲法与开放标签他汀治疗不良事件:ASCOT-LLA随机双盲试验及其非随机非盲扩展期

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
PubMed 文献 · Lancet · 2017-05-02
一句话结论盲法阶段阿托伐他汀10 mg每日与安慰剂肌肉相关不良事件无显著差异,非盲阶段他汀使用者肌肉相关不良事件显著增多,提示反安慰剂效应。

ASCOT-LLA在高血压且至少合并三个其他心血管危险因素、空腹总胆固醇≤6.5 mmol/L、未服用他汀或贝特类、无心肌梗死史且未因心绞痛治疗的患者中,先进行随机双盲安慰剂对照阶段(阿托伐他汀10 mg每日 vs 安慰剂),后因疗效提前终止而进入非随机非盲扩展期(所有患者开放标签阿托伐他汀10 mg每日)。盲法阶段肌肉相关不良事件两组相似(2.03%/年 vs 2.00%/年,HR 1.03,95%CI 0.88-1.21,p=0.72),睡眠障碍他汀组更低(1.00%/年 vs 1.46%/年,HR 0.69,95%CI 0.56-0.85,p=0.0005),肾脏与泌尿系统不良事件他汀组更多(1.87%/年 vs 1.51%/年,HR 1.23,95%CI 1.08-1.41,p=0.002)。非盲阶段他汀使用者肌肉相关不良事件报告率显著高于未使用者(1.26%/年 vs 1.00%/年,HR 1.41,95%CI 1.10-1.79,p=0.006), musculoskeletal and connective tissue disorders(8.69%/年 vs 7.45%/年,HR 1.17,95%CI 1.06-1.29,p=0.001)和血液淋巴系统疾病(0.88%/年 vs 0.64%/年,HR 1.40,95%CI 1.04-1.88,p=0.03)也更多。

要点

  • 盲法阶段阿托伐他汀10 mg每日与安慰剂肌肉相关不良事件相似:2.03%/年 vs 2.00%/年,HR 1.03(95%CI 0.88-1.21),p=0.72。
  • 非盲阶段他汀使用者肌肉相关不良事件报告率显著高于未使用者:1.26%/年 vs 1.00%/年,HR 1.41(95%CI 1.10-1.79),p=0.006。
  • 盲法阶段睡眠障碍他汀组显著低于安慰剂组:1.00%/年 vs 1.46%/年,HR 0.69(95%CI 0.56-0.85),p=0.0005。
  • 盲法阶段肾脏与泌尿系统不良事件他汀组更多:1.87%/年 vs 1.51%/年,HR 1.23(95%CI 1.08-1.41),p=0.002。
  • 作者认为这些分析说明反安慰剂效应,多数他汀相关不良事件并非因果相关。

适用人群与场景

  • 年龄40-79岁、高血压、至少合并三个其他心血管危险因素、空腹总胆固醇≤6.5 mmol/L、未服用他汀或贝特类、无心肌梗死史且未因心绞痛治疗的患者。

处置流程与药物剂量

  • 盲法随机阶段:阿托伐他汀10 mg每日口服 vs 匹配安慰剂。
  • 非随机非盲扩展期:所有患者开放标签阿托伐他汀10 mg每日口服。

研究设计与关键结果

  • 盲法随机双盲安慰剂对照阶段1998年2月至2002年12月,纳入10180例(阿托伐他汀组5101例,安慰剂组5079例),中位随访3.3年(IQR 2.7-3.7)。
  • 非盲非随机阶段2002年12月至2005年6月,纳入9899例(他汀使用者6409例,未使用者3490例),中位随访2.3年(IQR 2.2-2.4)。
  • 盲法阶段肌肉相关不良事件:阿托伐他汀组298例(2.03%/年)vs 安慰剂组283例(2.00%/年),HR 1.03(95%CI 0.88-1.21),p=0.72。
  • 盲法阶段勃起功能障碍:阿托伐他汀组272例(1.86%/年)vs 安慰剂组302例(2.14%/年),HR 0.88(95%CI 0.75-1.04),p=0.13。
  • 盲法阶段睡眠障碍:阿托伐他汀组149例(1.00%/年)vs 安慰剂组210例(1.46%/年),HR 0.69(95%CI 0.56-0.85),p=0.0005。
  • 盲法阶段认知障碍:阿托伐他汀组31例(0.20%/年)vs 安慰剂组32例(0.22%/年),HR 0.94(95%CI 0.57-1.54),p=0.81,病例数太少无法进行统计学可靠分析。
  • 盲法阶段肾脏与泌尿系统不良事件:阿托伐他汀组481例(1.87%/年)vs 安慰剂组392例(1.51%/年),HR 1.23(95%CI 1.08-1.41),p=0.002;其他报告的不良事件无显著差异。
  • 非盲阶段肌肉相关不良事件:他汀使用者161例(1.26%/年)vs 未使用者124例(1.00%/年),HR 1.41(95%CI 1.10-1.79),p=0.006;骨骼肌肉与结缔组织疾病992例(8.69%/年)vs 831例(7.45%/年),HR 1.17(95%CI 1.06-1.29),p=0.001;血液与淋巴系统疾病114例(0.88%/年)vs 80例(0.64%/年),HR 1.40(95%CI 1.04-1.88),p=0.03;其他不良事件无显著差异。

证据类型、等级与局限

  • 证据类型:随机双盲安慰剂对照试验及其非随机非盲扩展期。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些结果有助于让医生和患者确信多数他汀相关不良事件并非与药物使用因果相关,并有助于抵消夸大他汀相关副作用的说法对公共健康的不良影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials.

METHODS: In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk factors, and fasting total cholesterol concentrations of 6·5 mmol/L or lower, and who were not taking a statin or fibrate, had no history of myocardial infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-controlled phase. In a subsequent non-randomised non-blind extension phase (initiated because of early termination of the trial because efficacy of atorvastatin was shown), all patients were offered atorvastatin 10 mg daily open label. We classified AEs using the Medical Dictionary for Regulatory Activities. We blindly adjudicated all reports of four prespecified AEs of interest-muscle-related, erectile dysfunction, sleep disturbance, and cognitive impairment-and analysed all remaining AEs grouped by system organ class. Rates of AEs are given as percentages per annum.

RESULTS: The blinded randomised phase was done between February, 1998, and December, 2002; we included 101 80 patients in this analysis (5101 [50%] in the atorvastatin group and 5079 [50%] in the placebo group), with a median follow-up of 3·3 years (IQR 2·7-3·7). The non-blinded non-randomised phase was done between December, 2002, and June, 2005; we included 9899 patients in this analysis (6409 [65%] atorvastatin users and 3490 [35%] non-users), with a median follow-up of 2·3 years (2·2-2·4). During the blinded phase, muscle-related AEs (298 [2·03% per annum] vs 283 [2·00% per annum]; hazard ratio 1·03 [95% CI 0·88-1·21]; p=0·72) and erectile dysfunction (272 [1·86% per annum] vs 302 [2·14% per annum]; 0·88 [0·75-1·04]; p=0·13) were reported at a similar rate by participants randomly assigned to atorvastatin or placebo. The rate of reports of sleep disturbance was significantly lower among participants assigned atorvastatin than assigned placebo (149 [1·00% per annum] vs 210 [1·46% per annum]; 0·69 [0·56-0·85]; p=0·0005). Too few cases of cognitive impairment were reported for a statistically reliable analysis (31 [0·20% per annum] vs 32 [0·22% per annum]; 0·94 [0·57-1·54]; p=0·81). We observed no significant differences in the rates of all other reported AEs, with the exception of an excess of renal and urinary AEs among patients assigned atorvastatin (481 [1·87%] per annum vs 392 [1·51%] per annum; 1·23 [1·08-1·41]; p=0·002). By contrast, during the non-blinded non-randomised phase, muscle-related AEs were reported at a significantly higher rate by participants taking statins than by those who were not (161 [1·26% per annum] vs 124 [1·00% per annum]; 1·41 [1·10-1·79]; p=0·006). We noted no significant differences between statin users and non-users in the rates of other AEs, with the exception of musculoskeletal and connective tissue disorders (992 [8·69% per annum] vs 831 [7·45% per annum]; 1·17 [1·06-1·29]; p=0·001) and blood and lymphatic system disorders (114 [0·88% per annum] vs 80 [0·64% per annum]; 1·40 [1·04-1·88]; p=0·03), which were reported more commonly by statin users than by non-users.

INTERPRETATION: These analyses illustrate the so-called nocebo effect, with an excess rate of muscle-related AE reports only when patients and their doctors were aware that statin therapy was being used and not when its use was blinded. These results will help assure both physicians and patients that most AEs associated with statins are not causally related to use of the drug and should help counter the adverse effect on public health of exaggerated claims about statin-related side-effects.

FUNDING: Pfizer, Servier Research Group, and Leo Laboratories.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017. PMID: 28476288. doi:10.1016/S0140-6736(17)31075-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。